Lidocaine relieves murine allergic rhinitis by regulating the NF‑κB and p38 MAPK pathways

Xiang,Jing; Yang,Zhen; Zhou,Qiang

doi:10.3892/etm.2022.11116

Lidocaine relieves murine allergic rhinitis by regulating the NF‑κB and p38 MAPK pathways

Authors:
- Jing Xiang
- Zhen Yang
- Qiang Zhou
View Affiliations

Affiliations: Department of Anesthesiology, Wuhan Jinyintan Hospital, Wuhan, Hubei 430000, P.R. China
Published online on: January 5, 2022 https://doi.org/10.3892/etm.2022.11116
Article Number: 193
Copyright: © Xiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Allergic rhinitis (AR) is one of the most common chronic inflammatory diseases and its main feature is nasal mucositis. It has been recently revealed that lidocaine demonstrates optimal effects in the treatment of various diseases. However, a limited number of studies have examined the association between lidocaine and AR. In the present study, the AR mouse model was established to explore the effects of lidocaine in AR and to further analyze its molecular mechanism. Subsequently, different concentrations of lidocaine were provided to the animals by intranasal administration and a series of indices were assessed. The data indicated that the frequencies of mouse sneezing and nose rubbing were suppressed following an increase in lidocaine concentration. Subsequently, the number of inflammatory cells was measured. Wright's‑Giemsa staining results indicated that lidocaine significantly decreased the numbers of leukocytes, eosinophils, neutrophils and lymphocytes in the nasal lavage fluid (NLF) of AR mice. In addition, the expression levels of ovalbumin (OVA)‑specific immunoglobulin E (IgE), leukotriene C4 (LTC4) and certain inflammatory factors were assessed by ELISA. Lidocaine reduced OVA‑specific IgE and LTC4 expression in NLF and plasma derived from AR mice. It also decreased the expression levels of IL‑4, IL‑5, IL‑13, IL‑17 and TNF‑α. Lidocaine caused upregulation of IFN‑γ and IL‑2 expression levels. Subsequently, western blot analysis indicated that lidocaine suppressed phosphorylated (p)‑p38 and p‑p65 expression levels in AR mice. Collectively, the results indicated that the NF‑κB and p38 MAPK signaling pathways were involved in the lidocaine‑mediated relief of AR in mice. In order to further verify the association between the NF‑κB and p38 MAPK signaling pathways and AR in mice, the effects of the NF‑κB inhibitor IMD‑0354 and the p38 MAPK inhibitor SB 203580 were assessed on AR mice. The results indicated that these two compounds exhibited similar inhibitory effects on AR mice as those noted with the use of lidocaine. These findings suggested that lidocaine represented a novel therapeutic agent for AR.

View Figures

View References

1	Incorvaia C, Cavaliere C, Frati F and Masieri S: Allergic rhinitis. J Biol Regul Homeost Agents. 32 (1 Suppl 1):S61–S66. 2018.PubMed/NCBI
2	Paiva Ferreira LKD, Paiva Ferreira LAM, Monteiro TM, Bezerra GC, Bernardo LR and Piuvezam MR: Combined allergic rhinitis and asthma syndrome (CARAS). Int Immunopharmacol. 74(105718)2019.PubMed/NCBI View Article : Google Scholar
3	Rosati MG and Peters AT: Relationships among allergic rhinitis, asthma, and chronic rhinosinusitis. Am J Rhinol Allergy. 30:44–47. 2016.PubMed/NCBI View Article : Google Scholar
4	Prenner BM and Schenkel E: Allergic rhinitis: Treatment based on patient profiles. Am J Med. 119:230–237. 2006.PubMed/NCBI View Article : Google Scholar
5	Sur DK and Plesa ML: Treatment of allergic rhinitis. Am Fam Physician. 92:985–992. 2015.PubMed/NCBI
6	Bernstein DI, Schwartz G and Bernstein JA: Allergic rhinitis: Mechanisms and treatment. Immunol Allergy Clin North Am. 36:261–278. 2016.PubMed/NCBI View Article : Google Scholar
7	Steelant B, Farré R, Wawrzyniak P, Belmans J, Dekimpe E, Vanheel H, Van Gerven L, Kortekaas Krohn I, Bullens DM, Ceuppens JL, et al: Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression. J Allergy Clin Immunol. 137:1043–1053.e5. 2016.PubMed/NCBI View Article : Google Scholar
8	Lin S, Jin P, Shao C, Lu W, Xiang Q, Jiang Z, Zhang Y and Bian J: Lidocaine attenuates lipopolysaccharide-induced inflammatory responses and protects against endotoxemia in mice by suppressing HIF1α-induced glycolysis. Int Immunopharmacol. 80(106150)2020.PubMed/NCBI View Article : Google Scholar
9	Leng T, Lin S, Xiong Z and Lin J: Lidocaine suppresses glioma cell proliferation by inhibiting TRPM7 channels. Int J Physiol Pathophysiol Pharmacol. 9:8–15. 2017.PubMed/NCBI
10	Křikava I, Nováková M and Ševčík P: The effects of trimecaine on bupivacaine induced cardiotoxicity in the isolated rat heart: A pilot study. Physiol Res. 57(18)2008.
11	Martí-Carvajal AJ, Simancas-Racines D, Anand V and Bangdiwala S: Prophylactic lidocaine for myocardial infarction. Cochrane Database Syst Rev. 2015(CD008553)2015.PubMed/NCBI View Article : Google Scholar
12	Nakazawa M, Okumura A, Niijima S, Yamashita S, Shimono K, Hirose S and Shimizu T: Oral mexiletine for lidocaine-responsive neonatal epilepsy. Brain Dev. 35:667–669. 2013.PubMed/NCBI View Article : Google Scholar
13	Slaton RM, Thomas RH and Mbathi JW: Evidence for therapeutic uses of nebulized lidocaine in the treatment of intractable cough and asthma. Ann Pharmacother. 47:578–585. 2013.PubMed/NCBI View Article : Google Scholar
14	Chinn E, Friedman BW, Naeem F, Irizarry E, Afrifa F, Zias E, Jones MP, Pearlman S, Chertoff A, Wollowitz A and Gallagher EJ: Randomized trial of intravenous lidocaine versus hydromorphone for acute abdominal pain in the emergency department. Ann Emerg Med. 74:233–240. 2019.PubMed/NCBI View Article : Google Scholar
15	Liu H, Dilger JP and Lin J: Lidocaine suppresses viability and migration of human breast cancer Cells: TRPM7 as a target for some breast cancer cell lines. Cancers (Basel). 13(234)2021.PubMed/NCBI View Article : Google Scholar
16	Zhao L, Ma N, Liu G, Mao N, Chen F and Li J: Lidocaine inhibits hepatocellular carcinoma development by modulating circ_ITCH/miR-421/CPEB3 axis. Dig Dis Sci. 66:4384–4397. 2021.PubMed/NCBI View Article : Google Scholar
17	Lee U, Choi YJ, Choi GJ and Kang H: Intravenous lidocaine for effective pain relief after bimaxillary surgery. Clin Oral Investig. 21:2645–2652. 2017.PubMed/NCBI View Article : Google Scholar
18	Guang F, Liu S, Wang GL and Liu GJ: Lidocaine attenuates lipopolysaccharide-induced acute lung injury through inhibiting NF-kappaB activation. Pharmacology. 81:32–40. 2008.PubMed/NCBI View Article : Google Scholar
19	Lin S, Jin P, Shao C, Lu W, Xiang Q, Jiang Z, Zhang Y and Bian J: Lidocaine attenuates lipopolysaccharide-induced inflammatory responses and protects against endotoxemia in mice by suppressing HIF1α-induced glycolysis. Int Immunopharmacol. 80(106150)2020.PubMed/NCBI View Article : Google Scholar
20	Leon-Constantin MM, Alexa-Stratulat T, Luca A, Tamba BI, Trandafir LM, Harabagiu V and Cojocaru E: The morphofunctional impact of topical lidocaine formulation in inflammatory pain-experimental study. Rom J Morphol Embryol. 60:869–874. 2019.PubMed/NCBI
21	Wang L, Wang M, Li S, Wu H, Shen Q, Zhang S, Fang L and Liu R: Nebulized lidocaine ameliorates allergic airway inflammation via downregulation of TLR2. Mol Immunol. 97:94–100. 2018.PubMed/NCBI View Article : Google Scholar
22	Xiao L, Jiang L, Hu Q and Li Y: MicroRNA-133b ameliorates allergic inflammation and symptom in murine model of allergic rhinitis by targeting Nlrp3. Cell Physiol Biochem. 42:901–912. 2017.PubMed/NCBI View Article : Google Scholar
23	Xu H, Shu H, Zhu J and Song J: Inhibition of TLR4 inhibits allergic responses in murine allergic rhinitis by regulating the NF-κB pathway. Exp Ther Med. 18:761–768. 2019.PubMed/NCBI View Article : Google Scholar
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
25	Zheng Y, Hou X and Yang S: Lidocaine potentiates SOCS3 to attenuate inflammation in microglia and suppress neuropathic pain. Cell Mol Neurobiol. 39:1081–1092. 2019.PubMed/NCBI View Article : Google Scholar
26	Khan DA: Allergic rhinitis and asthma: Epidemiology and common pathophysiology. Allergy Asthma Proc. 35:357–361. 2014.PubMed/NCBI View Article : Google Scholar
27	Mandhane SN, Shah JH and Thennati R: Allergic rhinitis: An update on disease, present treatments and future prospects. Int Immunopharmacol. 11:1646–1662. 2011.PubMed/NCBI View Article : Google Scholar
28	Casale TB and Dykewicz MS: Clinical implications of the allergic rhinitis-asthma link. Am J Med Sci. 327:127–138. 2014.PubMed/NCBI View Article : Google Scholar
29	Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, Brignardello-Petersen R, Canonica GW, Casale T, Chavannes NH, et al: Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 140:950–958. 2017.PubMed/NCBI View Article : Google Scholar
30	Drazdauskaitė G, Layhadi JA and Shamji MH: Mechanisms of allergen immunotherapy in allergic rhinitis. Curr Allergy Asthma Rep. 21(2)2020.PubMed/NCBI View Article : Google Scholar
31	Wu S and Xiao D: Effect of curcumin on nasal symptoms and airflow in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 117:697–702.e1. 2016.PubMed/NCBI View Article : Google Scholar
32	Yu S, Han B, Liu S, Wang H, Zhuang W, Huang Y and Zhang R: Derp1-modified dendritic cells attenuate allergic inflammation by regulating the development of T helper type1(Th1)/Th2 cells and regulatory T cells in a murine model of allergic rhinitis. Mol Immunol. 90:172–181. 2017.PubMed/NCBI View Article : Google Scholar
33	Li J, Lin XY, Liu X, Ma ZQ and Li Y: Baicalin regulates Treg/Th17 cell imbalance by inhibiting autophagy in allergic rhinitis. Mol Immunol. 125:162–171. 2020.PubMed/NCBI View Article : Google Scholar
34	Bae JS, Kim JH, Kim EH and Mo JH: The role of IL-17 in a lipopolysaccharide-induced rhinitis model. Allergy Asthma Immunol Res. 9:169–176. 2017.PubMed/NCBI View Article : Google Scholar
35	Bachert C, Zhang L and Gevaert P: Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. J Allergy Clin Immunol. 136:1431–1440. 2015.PubMed/NCBI View Article : Google Scholar
36	Deo SS, Mistry KJ, Kakade AM and Niphadkar PV: Role played by Th2 type cytokines in IgE mediated allergy and asthma. Lung India. 27:66–71. 2010.PubMed/NCBI View Article : Google Scholar
37	Coffman RL, Seymour BW, Hudak S, Jackson J and Rennick D: Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science. 245:308–310. 1989.PubMed/NCBI View Article : Google Scholar
38	Jung HW, Jung JK and Park YK: Comparison of the efficacy of KOB03, ketotifen, and montelukast in an experimental mouse model of allergic rhinitis. Int Immunopharmacol. 16:254–260. 2013.PubMed/NCBI View Article : Google Scholar
39	Piao CH, Fan YJ, Nguyen TV, Song CH and Chai OH: Mangiferin alleviates ovalbumin-induced allergic rhinitis via Nrf2/HO-1/NF-κB signaling pathways. Int J Mol Sci. 21(3415)2020.PubMed/NCBI View Article : Google Scholar
40	Lawrence T: The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 1(a001651)2009.PubMed/NCBI View Article : Google Scholar
41	Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W and Haegeman G: p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem. 273:3285–3290. 1998.PubMed/NCBI View Article : Google Scholar
42	Dodeller F, Skapenko A, Kalden JR, Lipsky PE and Schulze-Koops H: The p38 mitogen-activated protein kinase regulates effector functions of primary human CD4 T cells. Eur J Immunol. 35:3631–3642. 2005.PubMed/NCBI View Article : Google Scholar
43	Dodeller F and Schulze-Koops H: The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells. Arthritis Res Ther. 8(205)2006.PubMed/NCBI View Article : Google Scholar
44	Ono K and Han J: The p38 signal transduction pathway: Activation and function. Cell Signal. 12:1–13. 2000.PubMed/NCBI View Article : Google Scholar
45	Kang OH, Jang HJ, Chae HS, Oh YC, Choi JG, Lee YS, Kim JH, Kim YC, Sohn DH, Park H and Kwon DY: Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: Pivotal roles of NF-kappaB and MAPK. Pharmacol Res. 59:330–337. 2009.PubMed/NCBI View Article : Google Scholar
46	Liu J, Liu L, Cui Y, Zhang J and Jiang H: p38 MAPK regulates Th2 cytokines release in PBMCs in allergic rhinitis rats. J Huazhong Univ Sci Technolog Med Sci. 30:222–225. 2010.PubMed/NCBI View Article : Google Scholar
47	Gao X, Li N and Zhang J: SB203580, a p38MAPK inhibitor, attenuates olfactory dysfunction by inhibiting OSN apoptosis in AR mice (activation and involvement of the p38 mitogen-activated protein kinase in olfactory sensory neuronal apoptosis of OVA-induced allergic rhinitis). Brain Behav. 9(e01295)2019.PubMed/NCBI View Article : Google Scholar
48	Jiang R, Liao J, Yang MC, Deng J, Hu YX, Li P and Li MT: Lidocaine mediates the progression of cerebral ischemia/reperfusion injury in rats via inhibiting the activation of NF-κB p65 and p38 MAPK. Ann Transl Med. 8(548)2020.PubMed/NCBI View Article : Google Scholar
49	Chen LJ, Ding YB, Ma PL, Jiang SH, Li KZ, Li AZ, Li MC, Shi CX, Du J and Zhou HD: The protective effect of lidocaine on lipopolysaccharide-induced acute lung injury in rats through NF-κB and p38 MAPK signaling pathway and excessive inflammatory responses. Eur Rev Med Pharmacol Sci. 22:2099–2108. 2018.PubMed/NCBI View Article : Google Scholar
50	Haller I, Hausott B, Tomaselli B, Keller C, Klimaschewski L, Gerner P and Lirk P: Neurotoxicity of lidocaine involves specific activation of the p38 mitogen-activated protein kinase, but not extracellular signal-regulated or c-jun N-terminal kinases, and is mediated by arachidonic acid metabolites. Anesthesiology. 105:1024–1033. 2006.PubMed/NCBI View Article : Google Scholar
51	Jin H and Yu J: Lidocaine protects H9c2 cells from hypoxia-induced injury through regulation of the MAPK/ERK/NF-κB signaling pathway. Exp Ther Med. 18:4125–4131. 2019.PubMed/NCBI View Article : Google Scholar
52	Niu L, Wei J, Li X, Jin Y and Shi X: Inhibitory activity of narirutin on RBL-2H3 cells degranulation. Immunopharmacol Immunotoxicol. 43:68–76. 2021.PubMed/NCBI View Article : Google Scholar
53	van der Wal SE, van den Heuvel SA, Radema SA, van Berkum BF, Vaneker M, Steegers MA, Scheffer GJ and Vissers KC: The in vitro mechanisms and in vivo efficacy of intravenous lidocaine on the neuroinflammatory response in acute and chronic pain. Eur J Pain. 20:655–674. 2016.PubMed/NCBI View Article : Google Scholar